Media headlines about Biocept (NASDAQ:BIOC) have trended somewhat positive recently, according to Accern. The research firm identifies negative and positive press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Biocept earned a media sentiment score of 0.09 on Accern’s scale. Accern also gave headlines about the medical research company an impact score of 45.861195155947 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Here are some of the headlines that may have effected Accern Sentiment’s analysis:

A number of brokerages recently commented on BIOC. Zacks Investment Research raised Biocept from a “sell” rating to a “hold” rating in a research note on Monday, August 27th. ValuEngine raised Biocept from a “hold” rating to a “buy” rating in a research note on Wednesday, August 15th. Finally, Westpark Capital lowered Biocept from an “outperform” rating to a “hold” rating in a research note on Wednesday, May 23rd.

BIOC stock traded down $0.03 on Tuesday, reaching $3.49. The company’s stock had a trading volume of 98,800 shares, compared to its average volume of 235,463. Biocept has a 12-month low of $2.86 and a 12-month high of $44.10. The firm has a market capitalization of $8.00 million, a price-to-earnings ratio of -0.15 and a beta of 1.63. The company has a quick ratio of 1.08, a current ratio of 1.20 and a debt-to-equity ratio of 0.42.

Biocept (NASDAQ:BIOC) last announced its quarterly earnings results on Tuesday, August 14th. The medical research company reported ($2.70) EPS for the quarter, topping analysts’ consensus estimates of ($3.30) by $0.60. Biocept had a negative return on equity of 587.80% and a negative net margin of 642.49%. The company had revenue of $0.82 million during the quarter, compared to analyst estimates of $1.09 million. equities research analysts anticipate that Biocept will post -9.01 earnings per share for the current year.

Biocept Company Profile

Biocept, Inc, an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms.

See Also: How Do You Make Money With Penny Stocks?

Insider Buying and Selling by Quarter for Biocept (NASDAQ:BIOC)

Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with's FREE daily email newsletter.